deltatrials
Terminated PHASE2 NCT00417690

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease

A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease

Sponsor: Jacobus Pharmaceutical

Conditions Crohn's Disease
Interventions 4-Aminosalicylic acid PASER placebo granules
Updated 7 times since 2017 Last updated: Oct 14, 2008 Started: Jan 31, 2007 Primary completion: Dec 31, 2007 Completion: Oct 31, 2008

This PHASE2 trial investigates Crohn's Disease and is currently terminated or withdrawn. Jacobus Pharmaceutical leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jacobus Pharmaceutical
Data source: Jacobus Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Charlotte, United States
  • • Chicago, United States
  • • Haifa, Israel
  • • New York, United States
  • • Tel Aviv, Israel